Precision Medicine Treatment in Acute Myeloid Leukemia Is Not a Dream

The development of molecular studies to define the somatic genetic alterations has revolutionized diagnostic and therapeutic management acute myeloid leukemia (AML). AML is a highly heterogenous disease that includes many subtypes; each subtype heterogeneous both for presence variable co-mutations complex combinations clones subclones, changing during evolution in response treatment. treatment from standardized schemes induction consolidation chemotherapy tailored approaches according profiles targeted therapy. Several molecularly therapies have been approved some patients, including mutation-specific drugs such as FLT3, IDH1 IDH2 inhibitors, mutation-independent Bcl2 inhibitor venetoclax, hedgehog glasdegib CD33-targeted drug gemtuzumab ozogamicin. Furthermore, recent shown feasibility personalized medicine approach where therapy decisions are guided by results genomic studies.